Retina

The 15th annual meeting, taking from March 24–28 in Snowmass, Colorado, will deliver high-impact discussions on macular disease, artificial intelligence in ophthalmology, and breakthrough therapies—plus opportunities for networking on and off the slopes.

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

A look at the current state of AI in diabetic eye disease and where the future may take us.

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when compared to the year prior.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.

Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

Within 4 months of AEYE-DS's deployment, diabetic retinopathy screening adherence increased from 29 percent to 49 percent.

The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries.

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies.

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in personalized ophthalmic care.

Avant Technologies and Ainnova Tech have partnered to develop a low-cost retinal camera integrated with Ainnova’s Vision AI platform for early detection of ocular and systemic diseases. The technology will be marketed as a SaaS platform for primary care settings.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for oculoplastic procedures from August 2018 to November 2020.

Options empower patients and providers to decrease treatment burden

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need for improved awareness, cost-effectiveness, and integration to increase diabetic retinopathy screening rates.

Vaidehi S. Dedania, MD, from the New York University (NYU) Langone Health and the Grossman School of Medicine, spoke with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. She insights from the session, "Preventing and managing complications following vitreoretinal surgery."

Vikas Chopra, MD, from the Doheny Eye Institute of UCLA, caught up with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. He shared how technology has advanced ophthalmic surgery over the years and how hands on sessions at the meeting allow surgeons to train for rare complications that can arise during routine surgeries.

Julie Schallhorn, MD, MS, also is an associate professor of ophthalmology at the University of California San Francisco, has drawn upon her bioengineering background to develop a device to simplify eye drop administration.

During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr., MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.

In a presentation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language models (LLMs) in revenue cycle management (RCM).

Michael Singer, MD, shared insights from on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.

In the first five months of the program at Henrietta Johnson Medical Center, 26% of patients with images gradable by EyeArt tested positive for either more-than-mild or vision-threatening diabetic retinopathy.

This initiative is supported by a $5 million grant from the Knights Templar Eye Foundation.